Business

The absence of a Marvel film to kick off the summer box office season in 2024 is a significant deviation from the trend seen since 2008. Over the past decade, Marvel Cinematic Universe films have consistently dominated the summer season with blockbuster openings. However, this year, the spotlight was on Universal’s “The Fall Guy,” which
0 Comments
Oddity Tech, a newly public Israeli cosmetics platform, has defied expectations by posting first-quarter results that exceeded projections. Utilizing artificial intelligence to develop products, the company reported earnings per share of 61 cents adjusted, compared to the expected 49 cents. Additionally, revenue reached $211.63 million, surpassing the $205 million anticipated by analysts. This performance reflects
0 Comments
Equinox, a high-end fitness chain, has made headlines by introducing one of the most expensive gym memberships in the world. The $40,000-per-year program, known as “Optimize by Equinox,” is tailored towards enhancing overall health and longevity. Partnering with lab-test startup Function Health, Equinox has developed a personalized health program that goes beyond traditional fitness routines.
0 Comments
Former Starbucks CEO, Howard Schultz, recently shared his thoughts on the coffee chain’s disappointing quarterly report, emphasizing that the key to recovery lies in enhancing its U.S. stores. Despite no longer holding a formal position at Starbucks, Schultz highlighted the necessity for improving the mobile order and pay experience and revamping the process of introducing
0 Comments
Amgen’s stock saw a significant increase of more than 12% following the release of positive initial data on its experimental weight loss injection. This development raised concerns among investors regarding potential competition in the weight loss drug market, causing shares of established players like Novo Nordisk and Eli Lilly to decline. Eli Lilly experienced a
0 Comments
The Federal Trade Commission (FTC) announced on Tuesday its intent to challenge numerous questionable patents held by pharmaceutical companies. These patents are associated with 20 different brand-name drugs, with Novo Nordisk’s popular drugs Ozempic, Saxenda, and Victoza among them. The FTC sent letters to 10 companies, including Novo Nordisk, AstraZeneca, Boehringer Ingelheim, Covis Pharma, GlaxoSmithKline,
0 Comments